SavedAdd your journal

Journals / Aksaray Üniversitesi Tıp Bilimleri Dergisi / 2026 / Cilt: 2 Sayı: 1

Treatment modalities in COVID 19

Rafiye Ciftciler(Aksaray University Training and Research Hospital, Department of Hematology)0000-0001-5687-8531
Ali Ciftciler(Ortaköy State Hospital, General Surgery, Aksaray)0000-0001-7612-2707
Pages
20–21
Publication Date
2021-07-03
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
🔖

Cite This Article

Ciftciler, R., Ciftciler, A. (2021). Treatment modalities in COVID 19. Aksaray Üniversitesi Tıp Bilimleri Dergisi, Cilt: 2 Sayı: 1, 20–21. https://ajindex.com/articles/1447462

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Organization WH. Coronavirus (COVID-19). 2020. 2020.
  2. Mishra E, Goyal AK, Rath G. Recent advances in drug delivery systems in antiviral therapy. 2018.
  3. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30(3):269-71.
  4. Oldfield V, Plosker GL. Lopinavir/ritonavir. Drugs. 2006;66(9):1275-99.
  5. Llibre JM. Development of darunavir over the entire spectrum of HIV infection. Enfermedades Infecciosas y Microbiologia Clinica. 2018;36:3-9.
  6. Khalili JS, Zhu H, Mak NSA, Yan Y, Zhu Y. Novel coronavirus treatment with ribavirin: Groundwork for an evaluation concerning COVID‐19. Journal of medical virology. 2020.
  7. Cao Y-c, Deng Q-x, Dai S-x. Remdesivir for severe acute respiratory syndrome coronavirus 2 causing COVID-19: An evaluation of the evidence. Travel Medicine and Infectious Disease. 2020:101647.
  8. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. Journal of Infection. 2020.
  9. Wang M, Cao R, Zhang L. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019 nCoV) in vitro [published online February 4, 2020]. Cell Res doi.10.
  10. Samuel CE. Antiviral actions of interferons. Clinical microbiology reviews. 2001;14(4):778-809.
  11. Olivares-Gazca JC, Priesca-Marín JM, Ojeda-Laguna M, Garces-Eisele J, Soto-Olvera S, Palacios-Alonso A, et al. Infusion of convalescent plasma is associated with clinical improvement in critically ill patients with COVID-19: a pilot study. Rev Invest Clin. 2020;72(3):159-64.
  12. Zhang C, Wu Z, Li J-W, Zhao H, Wang G-Q. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. International journal of antimicrobial agents. 2020:105954.
  13. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020;323(11):1061-9.
  14. Philippe G, Jean C, Lagier P. P.; Van, TH; Line, M.; et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial. Journal of Antimicrobial agents. 2020.
  15. Wu SC. Progress and Concept for COVID‐19 Vaccine Development. Biotechnology Journal. 2020.
  16. Çiftçiler R, Haznedaroğlu İ C. COVID-19, Renin-Angiotensin System, and Hematopoiesis. Turk J Haematol. 2020;37(3):207-8.